Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2513-2522

  Duffy, M J ^a   Lamerz, R ^b   Haglund, C ^c   Nicolini, A ^d   Kalousova M ^e   Holubec, L ^f   Sturgeon, C ^g  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF PISA   (Italy)

^e CHARLES UNIVERSITY   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

biomarker; colorectal cancer; EGTM; gastrointestinal cancer; guidelines; tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; STEM CELL FACTOR; TRASTUZUMAB; TUMOR MARKER;

CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; DISEASE COURSE; EARLY CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERMETHOD COMPARISON; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; OCCULT BLOOD TEST; ONCOGENE C KIT; ONCOGENE K RAS; PATIENT MONITORING; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; SYSTEMIC THERAPY;

BIOMARKER; COLORECTAL CANCER; EGTM; GASTROINTESTINAL CANCER; GUIDELINES; TUMOR MARKERS;

COLORECTAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; PRACTICE GUIDELINES AS TOPIC; STOMACH NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896400466     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28384     Document Type: Review

References (149)

1. Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003; 39: 718-27.
2. Duffy MJ, van Dalen A, Haglund C, et al. Tumor markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348-60.
3. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66.
4. Simon RM, Paik S, Hayes DF,. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-52.
5. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. Br Med J 2004; 328: 1490.
6. Pox C,. Colon cancer screening: which non-invasive filter tests Dig Dis 2011; 29 (Suppl 1): 56-9.
7. Zhu MM, Xu XT, Nie F, et al. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 2010; 11: 148-60.
8. Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using fecal the occult blood test, Hemoccult. Cochrane Database System Rev 2007.
9. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-9.
10. Duffy MJ, van Rossum LG, van Turenhout ST, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011; 128: 3-11.
11. Allison JE, Fraser CG, Halloran SP, et al. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology 2012; 142: 422-4.
12. Fraser CG,. A future for faecal haemoglobin measurements in the medical laboratory. Ann Clin Biochem 2012; 49: 518-26.
13. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155-9.
14. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462-147.
15. Segnan N, Patnik J, von Karsa L, eds. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: Publication Office of the European Union, 2010.
16. Wilson JM, Jungner YG,. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968; 65: 281-393.
17. Lansdorp-Vogelaar I, Knudsen AB, Brenner H,. Cost-effectiveness of colorectal cancer screening-an overview. Best Pract Res Clin Gastroenterol 2010; 24: 439-49.
18. Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US preventive services task force. Ann Intern Med 2002; 137: 96-104.
19. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost of savings of colorectal cancer screening. J Natl Cancer Inst 2009; 101; 1412-22.
20. Heitman SJ, Hilsden RJ, Au F, et al. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med 2010; 23; 7: e1000370.
21. Janneke A, Wilschut J, Dik F, et al. Faecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst 2011; 103: 1741-51.
22. Berchi C, Bouvier V, Réaud JM, et al. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ 2004; 13: 227-38.
23. Berchi C, Guittet L, Bouvier V, et al. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Int J Technol Assess Health Care 2010; 26: 48-53.
24. Grazzini G, Ciatto S, Cislaghi C, et al. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence. J Med Screen 2008; 15: 175-81.
25. van Rossum LG, van Rijn AF, Verbeek AL, et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac faecal occult blood tests: a cost-effectiveness analysis. Int J Cancer 2010; 128; 1908-17.
26. Fraser CG, Allison JE, Halloran SP, et al. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Instit 2012; 104: 810-14.
27. Bosch LJ, Carvalho B, Fijneman RJ, et al. Molecular tests for colorectal cancer screening. Clin Colorectal Cancer 2011; 10: 8-23.
28. Duffy MJ,. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful Clin Chem 2001; 47: 624-30.
29. Goldstein MJ, Mitchell EP,. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23: 338-51.
30. Thirunavukarasu P, Sukumar S, Sathaiah M, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst 2011; 103: 689-97.
31. Huh JW, Oh BR, Kim HR, et al. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. J Surg Oncol 2010; 101: 396-400.
32. Sun LC, Chu KS, Cheng SC, et al. Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer 2009; 9: 288.
33. Park IJ, Choi G-S, Lim KH, et al. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 2009; 16: 3087-93.
34. Peng Y, Wang L, Gu J,. Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. World J Surg 2013; 37: 208-13.
35. Park YJ, Park KJ, Park JG, et al. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg 1999; 23: 721-6.
36. Harrison LE, Guillem JG, Paty P, et al. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 1997; 185: 55-9.
37. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
38. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Colorectal Cancer Screening. Version 1.2013. Available at: http://www.nccn.org/physician-glsPDF/colorectal-screening.pdf Accessed, Dcember 18, 2012.
39. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54: e11-79.
40. Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v70-7.
41. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88: 1739-57.
42. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. Arch Pathol Lab Med 2000; 124: 979-94.
43. Scheer A, Auer RA,. Surveillance after curative resection of colorectal cancer. Clin Colon Rectal Surg 2009; 22: 242-50.
44. Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219: 174-82.
45. Rosen M, Chan L, Beart RW, Jr., et al. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum 1998; 41: 1116-26.
46. Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Br Med J 2002; 324: 813-20.
47. Jeffrey GM, Hickey BE,. Follow-up strategies for patients treated for nonmetastatic colorectal cancer (Cochrane Review). The Cochrane Library. Vol. Chichester, UK: Wiley, 2004.
48. Figueredo A, Rumble RB, Maroun J, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 2003; 3: 26-38.
49. Tjandra JJ, Chan MK,. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 2007; 50: 1783-99.
50. Sugarbaker PH, Gianola FJ, Dwyer A, et al. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987; 102: 7987.
51. Rocklin MS, Senagore AJ, Talbott TM,. Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinoma. Dis Colon Rectum 1991; 34: 794-7.
52. Nicolini A, Ferrari P, Duffy MJ, et al. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. Arch Surg 2010; 145: 1177-83.
53. Tsikitis VL, Malireddy K, Green EA, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 2009; 27: 3671-6.
54. Borie F, Combescure C, Daurès JP, et al. Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model. World J Surg 2004; 28: 563-9.
55. Renehan AG, O'Dwyer ST, Whynes DK,. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. Br Med J 2004; 328: 81.
56. Graham RA, Wang S, Catalano PJ, et al. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest X-ray, and colonoscopy. Ann Surg 1998; 228: 59-63.
57. Ruibal Morell A,. CEA serum levels in non-neoplastic disease. Int J Biol Markers 1992; 7: 160-6.
58. Sturgeon CM, Lai LC, Duffy MJ,. Serum tumour markers: how to order and interpret them. Br Med J 2009; 239: b3527.
59. Chao M, Gibbs P,. Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J Clin Oncol 2009; 27: e279-e80; author reply e281.
60. Therasse P, Eisenhauer EA, Verweij J,. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42: 1031-9.
61. de Haas RJ, Wicherts DA, Flores E, et al. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 2010; 17: 1010-23.
62. Iwanicki-Caron I, Di Fiore F, Roque I, et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008; 26: 3681-6.
63. Ward U, Primrose JN, Finan PJ, et al. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993; 67: 1132-5.
64. Strimpakos AS, Cunningham D, Mikropoulos C, et al. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol 2010; 21: 1013-9.
65. Ailawadhi S, Sunga A, Rajput A, et al. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 2006; 70: 49-53.
66. De La Chapelle A, Hampel H,. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 2010; 28: 3380-7.
67. Hewish M, Lord CJ, Martin SA, et al. Mismatch repair deficient colorectal cancer in the era of personalised treatment. Nat Rev Clin Oncol 2010; 7: 197-207.
68. Boland CR, Goel A,. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87.
69. Lastra E, García-González M, Llorente B, et al. Lynch syndrome diagnostics: decision-making process for germ-line testing. Clin Transl Oncol 2012; 14: 254-62.
70. Win AK, Lindor NM, Winship I, et al. Risks of colorectal and other cancers after endometrial cancer for women with lynch syndrome. J Natl Cancer Inst 2013; 105: 274-9.
71. Vasen HF, Abdirahman M, Brohet R, et al. Gastroenterology. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010; 138: 2300-6.
72. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary non-polyposis colorectal cancer. Gastroenterology 2000; 118: 829-34.
73. de Jong AE, Hendriks YMC, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006; 130: 665-71.
74. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354: 261-9.
75. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Group on HNPCC. Gastroenterology 1999; 116: 1453-6.
76. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Instit 1997; 89: 1758-62.
77. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Instit 2004; 96: 261-8.
78. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 2012; 61: 865-72.
79. Moreira L, Balaguer F, Lindor N, et al. EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308: 1555-65.
80. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009; 11: 42-65.
81. Weissman SM, Burt R, Church J, et al. Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. J Genet Couns 2012; 21: 484-93.
82. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011; 155: 69-79.
83. Popat S, Hubner R, Houlston RS,. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18.
84. Guastadisegni C, Colafranceschi M, Ottini L, et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 2010; 46: 2788-98.
85. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57.
86. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-26.
87. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29: 1261-70.
88. Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer-a study of CALGB 9581 and 89803. J Clin Oncol 2011; 29: 3153-62.
89. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II Colon Cancer. J Clin Oncol 2011; 29: 4611-9.
90. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012; 104: 1635-46.
91. Jover R, Zapater P, Castells A, et al. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009; 45: 365-73.
92. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer A systematic review with meta-analysis. Eur J Cancer 2009; 45: 1890-6.
93. Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-50.
94. Hemminki A, Mecklin JP, Järvinen H, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921-8.
95. Bardelli A, Siena S,. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-61.
96. Brand TM, Iida M, Wheeler DL,. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 2011; 71: 777-92.
97. Grothey A,. EGFR antibodies in colorectal cancer: where do they belong J Clin Oncol 2010; 28: 4668-70.
98. Loupakis F, Cremolini C, Salvatore L, et al. Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. Cancer 2012; 118: 1523-32.
99. Dahabreh IJ, Terasawa T, Castaldi PJ, et al. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Int Med 2011; 154: 37-49.
100. Wheeler DL, Dunn EF, Harari PM,. Understanding resistance to EGFR inhibitors: impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507.
101. Ballestrero A, Garuti A, Cirmena G, et al. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr Cancer Drug Targets 2012; 12: 316-28.
102. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-20.
103. Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-7.
104. Vijayaraghavan A, Efrusy MB, Göke B, et al. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 2012; 131: 438-45.
105. Linardou H, Briasoulis E, Dahabreh IJ, et al. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 2011; 37: 221-33.
106. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
107. Mao C, Yang ZY, Hu XF, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012; 23: 1518-25.
108. Bokemeyer C, Cutsem EV, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 146-75.
109. Yeung Y, Tebbutt NC,. Bevacizumab in colorectal cancer: current and future directions. Expert Rev Anticancer Ther 2012; 12: 1263-73.
110. Stein A, Glockzin G, Wienke A, et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer 2012; 12: 356.
111. Gaya A, Tse V,. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 2012; 38: 484-93.
112. Grothey A, Van Cutsem E, Sobrero A, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-12.
113. Davis SL, Eckhardt SG, Messersmith WA, et al. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today 2013; 49: 105-15.
114. Kopetz S, Desai J, Chan J, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010; 28: 15 s (abstract 3534).
115. Spreafico A, Tentler JJ, Pitts TM, et al. Rational combination of a MEK inhibitor, Selumetinib, and the Wnt/calcium pathway modulator, Cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res 2013.
116. Martinelli E, Troiani T, D'Aiuto E, et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer 2013.
117. Ng K, Tabernero J, Hwang JJ, et al. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-based regimens. Clin Cancer Res 2013; 19: 3987-95.
118. Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012; 30: 3588-95.
119. Smyth EC, Cunningham D,. targeted therapy for gastric cancer. Curr Treat Options Oncol 2012; 13: 377-89.
120. Matsui Y, Inomata M, Tojigamori M, et al. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005; 27: 681-5.
121. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007; 59: 795-805.
122. Bang YJ, Van Cutsem E, Feyereislova A, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97. Erratum in: Lancet. 2010;376:1302.
123. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virch Arch 2010; 457: 299-307.
124. Warneke VS, Behrens HM, Böger C, et al. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 2013; 24: 725-33.
125. Antonescu CR,. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011; 223: 251-61.
126. Blay JY, von Mehren M, Blackstein ME,. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010; 116: 5126-37.
127. Reichardt P, Blay J-Y, von Mehren M,. Towards a global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther 2010; 10: 221-32.
128. Nishida T, Hirota S, Yanagisawa A, et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol 2008; 13: 416-30.
129. The ESMO/European Sarcoma Network Working Group Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii49-vii55.
130. Blay JY, Landi B, Bonvalot S, et al. Recommendations for the management of GIST patients. Bull Cancer 2005; 92: 907-18.
131. NCCN guidelines Version 2.2012, Gastrointestinal stromal tumors. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed 23 December 2012.
132. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.
133. Verweij J, van Oosterom A, Blay J-Y, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-11.
134. Debiec-Rychter M, Dumez H, Judson I, et al. EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40: 689-95.
135. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-7.
136. Debiec-Rychter M, Sciot R, Le Cesne A, et al. EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-103.
137. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-32.
138. Gramza AW, Heinrich MC,. Optimizing the treatment of gastrointestinal stromal tumors: the role of genotyping. Am Soc Clin Oncol Ed Book 2010; 454-8.
139. Reichardt P, Blay JY, Boukovinas I, et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol 2012; 23: 2776-81.
140. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17-24.
141. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 2011; 29: 4620-6.
142. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage ii colon cancer. J Clin Oncol 2011; 29: 4611-9.
143. Birgisson H, Nielsen HJ, Christensen IJ, et al. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer 2010; 46: 3323-31.
144. Yakabe T, Nakafusa Y, Sumi K, et al. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol 2010; 17: 2349-56.
145. Berger BM, Ahlquist DA,. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology 2012; 44: 80-8.
146. Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 2011; 9: 133.
147. Ebert MP, Tänzer M, Balluff B, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med 2012; 366: 44-53.
148. Louhimo J, Kokkola A, Alfthan H, et al. Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer. Int J Cancer 2004; 111: 929-33.
149. Novelli M, Rossi S, Rodriguez-Justo M, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010; 57: 259-70.